U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H25BrN4O2
Molecular Weight 457.364
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of JNJ-26483327

SMILES

COC1=C2OCCCCCN(C)CC3=CC=C(Br)C=C3NC4=NC=NC(=C1)C4=C2

InChI

InChIKey=JXDYOSVKVSQGJM-UHFFFAOYSA-N
InChI=1S/C22H25BrN4O2/c1-27-8-4-3-5-9-29-21-11-17-19(12-20(21)28-2)24-14-25-22(17)26-18-10-16(23)7-6-15(18)13-27/h6-7,10-12,14H,3-5,8-9,13H2,1-2H3,(H,24,25,26)

HIDE SMILES / InChI

Approval Year

Name Type Language
4,6-ETHENOPYRIMIDO(4,5-B)(6,1,12)BENZOXADIAZACYCLOPENTADECINE, 17-BROMO-1,8,9,10,11,12,13,14-OCTAHYDRO-20-METHOXY-13-METHYL-
Preferred Name English
JNJ-26483327
Code English
JNJ 26483327 [WHO-DD]
Common Name English
17-BROMO-1,8,9,10,11,12,13,14-OCTAHYDRO-20-METHOXY-13-METHYL-4,6-ETHENOPYRIMIDO(4,5-B)(6,1,12)BENZOXADIAZACYCLOPENTADECINE
Systematic Name English
Code System Code Type Description
SMS_ID
300000051555
Created by admin on Tue Apr 01 16:30:55 GMT 2025 , Edited by admin on Tue Apr 01 16:30:55 GMT 2025
PRIMARY
ChEMBL
CHEMBL3545133
Created by admin on Tue Apr 01 16:30:55 GMT 2025 , Edited by admin on Tue Apr 01 16:30:55 GMT 2025
PRIMARY
CAS
807640-87-5
Created by admin on Tue Apr 01 16:30:55 GMT 2025 , Edited by admin on Tue Apr 01 16:30:55 GMT 2025
PRIMARY
MANUFACTURER PRODUCT INFORMATION
JNJ-26483327
Created by admin on Tue Apr 01 16:30:55 GMT 2025 , Edited by admin on Tue Apr 01 16:30:55 GMT 2025
PRIMARY
CLINICAL_TRIALS.GOV
JNJ-26483327
Created by admin on Tue Apr 01 16:30:55 GMT 2025 , Edited by admin on Tue Apr 01 16:30:55 GMT 2025
PRIMARY Official Title: An Open-label, Phase I Study to Determine the Safety and Pharmacokinetics of JNJ-26483327, a Multi-targeted Kinase Inhibitor, Administered to Subjects With Advanced Stage and/or Refractory Solid MalignanciesDetailed Description:JNJ-26483327, a multi-targeted reversible kinase inhibitor, is a new drug in development for treatment of cancer. This study will test the safety (the effect on the body) of JNJ-26483327 and the highest dose of JNJ-26483327 that patients with advanced cancer can tolerate will be determined. Antitumor activity of JNJ-26481585 will be evaluated.
PUBCHEM
11952856
Created by admin on Tue Apr 01 16:30:55 GMT 2025 , Edited by admin on Tue Apr 01 16:30:55 GMT 2025
PRIMARY
FDA UNII
16720VER1H
Created by admin on Tue Apr 01 16:30:55 GMT 2025 , Edited by admin on Tue Apr 01 16:30:55 GMT 2025
PRIMARY
NCI_THESAURUS
C77866
Created by admin on Tue Apr 01 16:30:55 GMT 2025 , Edited by admin on Tue Apr 01 16:30:55 GMT 2025
PRIMARY